Hunan Er-Kang Pharmaceutical Hits Day Low at CNY 3.44 Amid Price Pressure

Hunan Er-Kang Pharmaceutical Co., Ltd. experienced a significant decline in its stock performance today, with a drop of 6.7% as of March 23, 2026. The stock reached an intraday low of CNY 3.44, reflecting ongoing challenges within the company. Over the past week, Hunan Er-Kang has seen a more pronounced decline of 14.07%, while its monthly performance shows a decrease of 6.2%. In contrast, the broader China Shanghai Composite index has also faced losses, but at a lesser rate of 6.65% for the week and 6.58% for the month. Despite a year-to-date gain of 2.05%, the company has struggled with long-term growth, evidenced by a negative annual growth rate in net sales of 12.85% and a staggering decline in operating profit of 239.61% over the last five years. The company's market capitalization stands at CNY 5,248 million, positioning it within the mid-cap segment of the pharmaceuticals and biotechnology industry. With a return on equity of -7.49% and a return on capital employed of just 0.47%, Hunan Er-Kang continues to face significant operational hurdles.